Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
March 5, 2026
-
BUSINESS Takeda Targets Psoriasis Market with Zasocitinib, Touts Edge in TYK2 Selectivity
March 4, 2026
-
BUSINESS Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
-
BUSINESS Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
March 3, 2026
-
ORGANIZATION EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
March 2, 2026
-
BUSINESS Ono, AstraZeneca to End Japan Co-Promotion of Forxiga
March 2, 2026
-
BUSINESS Asahi Kasei to Buy German Antiviral Specialist Aicuris for 143.1 Billion Yen
February 27, 2026
-
BUSINESS Japan Pharma Market Up 1.7% in 2025, 5th Straight Year of Growth: IQVIA
February 26, 2026
-
COMMENTARY G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands
February 25, 2026
-
BUSINESS Nippon Kayaku Aims to Lift New Drug Sales Ratio to 30%, Bolsters Oncology Push
February 25, 2026
-
REGULATORY Japan Panel to Review Haihe’s PI3Kα Inhibitor, MSD’s HIV Med, and More on March 2
February 24, 2026
-
BUSINESS Daiichi Sankyo Taps Ex-Novartis CMO John Tsai as R&D Head
February 24, 2026
-
BUSINESS DMD Gene Therapy Elevidys Hits Japan Market at Record Price
February 20, 2026
-
REGULATORY Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
-
REGULATORY Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
-
BUSINESS Japan IP High Court Upholds Invalidation of Key Trazenta Dosage Patent
February 19, 2026
-
BUSINESS ONODERA GT Pharma Targets 2026 Filings for Two Gene Therapies
February 19, 2026
-
COMMENTARY Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?
February 18, 2026
-
BUSINESS Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026
-
BUSINESS Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
February 17, 2026
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…